Cargando…
E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements
Loss of E-cadherin expression due to mutation of the CDH1 gene is a characteristic feature of invasive lobular breast cancer (ILBC). Beta-catenin, which binds to the cytoplasmic domain of E-cadherin, is simultaneously downregulated, reflecting disassembly of adherens junctions (AJs) and loss of cell...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685979/ https://www.ncbi.nlm.nih.gov/pubmed/32572153 http://dx.doi.org/10.1038/s41379-020-0591-3 |
_version_ | 1783613273379176448 |
---|---|
author | Christgen, Matthias Bartels, Stephan van Luttikhuizen, Jana L. Bublitz, Janin Rieger, Luisa U. Christgen, Henriette Stark, Helge Sander, Bjoern Lehmann, Ulrich Steinemann, Doris Derksen, Patrick W. B. Kreipe, Hans |
author_facet | Christgen, Matthias Bartels, Stephan van Luttikhuizen, Jana L. Bublitz, Janin Rieger, Luisa U. Christgen, Henriette Stark, Helge Sander, Bjoern Lehmann, Ulrich Steinemann, Doris Derksen, Patrick W. B. Kreipe, Hans |
author_sort | Christgen, Matthias |
collection | PubMed |
description | Loss of E-cadherin expression due to mutation of the CDH1 gene is a characteristic feature of invasive lobular breast cancer (ILBC). Beta-catenin, which binds to the cytoplasmic domain of E-cadherin, is simultaneously downregulated, reflecting disassembly of adherens junctions (AJs) and loss of cell adhesion. E-cadherin to P-cadherin expression switching can rescue AJs and cell adhesion. However, P-cadherin has not been implicated in ILBC, so far. We aimed to characterize 13 ILBCs with exceptional histomorphology, which we termed ILBCs with tubular elements. The CDH1 mutational status was determined by next generation sequencing and whole-genome copy number (CN) profiling. Expression of cadherins was assessed by immunohistochemistry. ILBCs with tubular elements were ER-positive (13/13) and HER2-negative (13/13) and harbored deleterious CDH1 mutations (11/13) accompanied by loss of heterozygosity due to deletion of chromosome 16q22.1 (9/11). E-cadherin expression was lost or reduced in noncohesive tumor cells and in admixed tubular elements (13/13). Beta-catenin expression was lost in noncohesive tumor cells, but was retained in tubular elements (11/13), indicating focal rescue of AJ formation. N-cadherin and R-cadherin were always negative (0/13). Strikingly, P-cadherin was commonly positive (12/13) and immunoreactivity was accentuated in tubular elements. Adjacent lobular carcinoma in situ (LCIS) was always P-cadherin-negative (0/7). In a reference cohort of LCIS specimens, P-cadherin was constantly not expressed (0/25). In a reference cohort of invasive mammary carcinomas, P-cadherin-positive cases (36/268, 13%) were associated with triple-negative nonlobular breast cancer (P < 0.001). Compared with ILBCs from the reference cohort, P-cadherin expression was more common in ILBCs with tubular elements (12/13 versus 7/84, P < 0.001). In summary, E-cadherin to P-cadherin switching occurs in a subset of ILBCs. P-cadherin is the molecular determinant of a mixed-appearing histomorphology in ILBCs with tubular elements. |
format | Online Article Text |
id | pubmed-7685979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-76859792020-12-03 E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements Christgen, Matthias Bartels, Stephan van Luttikhuizen, Jana L. Bublitz, Janin Rieger, Luisa U. Christgen, Henriette Stark, Helge Sander, Bjoern Lehmann, Ulrich Steinemann, Doris Derksen, Patrick W. B. Kreipe, Hans Mod Pathol Article Loss of E-cadherin expression due to mutation of the CDH1 gene is a characteristic feature of invasive lobular breast cancer (ILBC). Beta-catenin, which binds to the cytoplasmic domain of E-cadherin, is simultaneously downregulated, reflecting disassembly of adherens junctions (AJs) and loss of cell adhesion. E-cadherin to P-cadherin expression switching can rescue AJs and cell adhesion. However, P-cadherin has not been implicated in ILBC, so far. We aimed to characterize 13 ILBCs with exceptional histomorphology, which we termed ILBCs with tubular elements. The CDH1 mutational status was determined by next generation sequencing and whole-genome copy number (CN) profiling. Expression of cadherins was assessed by immunohistochemistry. ILBCs with tubular elements were ER-positive (13/13) and HER2-negative (13/13) and harbored deleterious CDH1 mutations (11/13) accompanied by loss of heterozygosity due to deletion of chromosome 16q22.1 (9/11). E-cadherin expression was lost or reduced in noncohesive tumor cells and in admixed tubular elements (13/13). Beta-catenin expression was lost in noncohesive tumor cells, but was retained in tubular elements (11/13), indicating focal rescue of AJ formation. N-cadherin and R-cadherin were always negative (0/13). Strikingly, P-cadherin was commonly positive (12/13) and immunoreactivity was accentuated in tubular elements. Adjacent lobular carcinoma in situ (LCIS) was always P-cadherin-negative (0/7). In a reference cohort of LCIS specimens, P-cadherin was constantly not expressed (0/25). In a reference cohort of invasive mammary carcinomas, P-cadherin-positive cases (36/268, 13%) were associated with triple-negative nonlobular breast cancer (P < 0.001). Compared with ILBCs from the reference cohort, P-cadherin expression was more common in ILBCs with tubular elements (12/13 versus 7/84, P < 0.001). In summary, E-cadherin to P-cadherin switching occurs in a subset of ILBCs. P-cadherin is the molecular determinant of a mixed-appearing histomorphology in ILBCs with tubular elements. Nature Publishing Group US 2020-06-22 2020 /pmc/articles/PMC7685979/ /pubmed/32572153 http://dx.doi.org/10.1038/s41379-020-0591-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Christgen, Matthias Bartels, Stephan van Luttikhuizen, Jana L. Bublitz, Janin Rieger, Luisa U. Christgen, Henriette Stark, Helge Sander, Bjoern Lehmann, Ulrich Steinemann, Doris Derksen, Patrick W. B. Kreipe, Hans E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements |
title | E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements |
title_full | E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements |
title_fullStr | E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements |
title_full_unstemmed | E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements |
title_short | E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements |
title_sort | e-cadherin to p-cadherin switching in lobular breast cancer with tubular elements |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685979/ https://www.ncbi.nlm.nih.gov/pubmed/32572153 http://dx.doi.org/10.1038/s41379-020-0591-3 |
work_keys_str_mv | AT christgenmatthias ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT bartelsstephan ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT vanluttikhuizenjanal ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT bublitzjanin ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT riegerluisau ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT christgenhenriette ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT starkhelge ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT sanderbjoern ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT lehmannulrich ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT steinemanndoris ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT derksenpatrickwb ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements AT kreipehans ecadherintopcadherinswitchinginlobularbreastcancerwithtubularelements |